LONDON, April 10, 2014 /PRNewswire/ --
The US markets saw a positive sentiment on Wednesday, April 09, 2014, with the NASDAQ Composite closing at 4,183.90, up 1.72%, the Dow Jones Industrial Average ending the session at 16,437.18, up 1.11%, and the S&P 500 edging 1.09% higher to finish the trading session at 1,872.18. The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including E-Commerce China Dangdang Inc. (NYSE: DANG), Neuralstem Inc. (NYSE: CUR), Cytokinetics Inc. (NASDAQ: CYTK) and Nu Skin Enterprises Inc. (NYSE: NUS). Free technical research on DANG, CUR, CYTK and NUS can be downloaded upon signing up at:
Shares in E-Commerce China Dangdang Inc. edged 12.69% higher, finishing Wednesday's session at $14.56. The stock fluctuated between $13.11 and $14.62 during the session with a trading volume of 6.01 million shares as compared with its three months average volume of 4.53 million shares. Shares in E-Commerce China Dangdang Inc. have rallied 13.31% in the previous three trading sessions, 55.22% in the last three months, and 52.46% on YTD basis. The S&P 500 Consumer Discretionary Sector Index mapped a gain of 1.08% during the trading session, while the same has declined 3.84% in the last one month. The company's stock is trading above its 50-day and 200-day moving averages of $12.90 and $10.11, respectively. Furthermore, the company's stock has a Relative Strength Index (RSI) of 42.63. Sign up today to read free research on DANG at:
On Wednesday, Neuralstem Inc.'s stock ended the session at $4.66, up 8.37%. A total of 1.68 million shares were traded as compared with its three months average volume of 1.12 million shares. During the session, the stock traded between $4.27 and $4.69. Neuralstem Inc.'s shares have rallied 31.64% in the past one month, 24.60% in the previous three months, and 60.14% on YTD basis. The S&P 500 Health Care Sector Index mapped a gain of 2.11% during the trading session, while the same has declined 2.01% in the last one month. Further, the company's stock has an RSI of 57.44 and is trading above its 50-day and 200-day moving averages of $3.69 and $2.63, respectively. Sign up today to read free research on CUR at:
Cytokinetics Inc.'s stock finished Wednesday's session at $9.90, up 11.49%. A total of 1.31 million shares were traded which is above its three months average volume of 0.87 million shares. The stock vacillated between $8.90 and $9.94 during the session. Cytokinetics Inc.'s shares have surged 13.01% in the previous three trading sessions, 18.56% in the last three months, and 52.31% on YTD basis. The S&P 500 Health Care Sector Index mapped a gain of 2.11% during the trading session, and the same has advanced 2.86% in the last three months. Additionally, the company's stock has an RSI of 44.03 and is trading above its 50-day and 200-day moving averages of $9.27 and $8.86, respectively. Sign up today to read free research on CYTK at:
Shares in Nu Skin Enterprises Inc. closed Wednesday's session at $85.74, up 5.68%, after oscillating between $81.60 and $86.15. A total of 1.41 million shares were traded, which is below its three months average volume of 3.02 million shares. Shares in Nu Skin Enterprises Inc. have advanced 12.37% in the last one month, while the same has declined 37.83% in the previous three months and 37.97% on YTD basis. The S&P 500 Consumer Staples Sector Index mapped a gain of 0.45% during the trading session and 2.06% in the last one month. Moreover, the company's stock has an RSI of 48.71 and is trading at a PE ratio of 14.43 and also above its 50-day moving average of $79.37. Sign up today to read free research on NUS at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.